Vivus Inc. (NASDAQ:VVUS) investor First Manhattan Co. believes its proposed director slate can realize the blockbuster potential of obesity drug Qsymia phentermine/topiramate.

Vivus launched Qsymia in September, but sales have disappointed. The biotech reported 4Q12 revenues of $2 million and attributed the slow uptake to the lack of reimbursement and the need to create a market for the drug (see BioCentury, Nov. 12, 2012).